APA (7th ed.) Citation

S, K., G, N., M, K., UM, F., C, P., AM, B., . . . J, L. (2024). GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA). Journal of neurology, 271(10), 6991. https://doi.org/10.1007/s00415-024-12647-z

Chicago Style (17th ed.) Citation

S, Katzdobler, et al. "GFAP and NfL as Fluid Biomarkers for Clinical Disease Severity and Disease Progression in Multiple System Atrophy (MSA)." Journal of Neurology 271, no. 10 (2024): 6991. https://doi.org/10.1007/s00415-024-12647-z.

MLA (9th ed.) Citation

S, Katzdobler, et al. "GFAP and NfL as Fluid Biomarkers for Clinical Disease Severity and Disease Progression in Multiple System Atrophy (MSA)." Journal of Neurology, vol. 271, no. 10, 2024, p. 6991, https://doi.org/10.1007/s00415-024-12647-z.